Tag Archive for: partnership

Nxera Pharma Ltd has got a Phase II milestone from US licencor Neurocrine Biosciences for its first-in class oral schizophrenia candidate NBI-1117568.

Danish ADC maker Adcendo ApS has licenced the rights to commercialise Multitude Therapeutics Inc’s first-in-class ADCE-T02 globally except the Greater China region.

Good news for BioNTech SE: The safety study of the ADC BNT326/YL202 developed by MediLink Therapeutics, which was suspended by the FDA in mid-June, will continue.

After Sangamo Therapeutics Inc. presented an epigenetic ZFN-based repressor at ASGCT 2024 that reduces the expression of the tau protein in the hippocampus by 95% in Alzheimer’s models, Roche’s US subsidiary Genentech has licensed the experimental gene therapy.

As one of the last Big Pharma companies, GlaxoSmithKline plc has inked a drug discovery licence option deal for up to 10 programmes with US-based biotech platform company supplier Flagship Pioneering Inc.

EuroscreenFast’s headquarters in Charleroi: @ EuroScreenFast

Belgium-headquarted GCPR-screening specialist EuroscreenFast and Asian distributor GW Vitek have inked a strategic collaboration.

Possible causes of ME/CFS. By w:Government Accountability Office - https://www.gao.gov/products/gao-22-105666, Public Domain, https://commons.wikimedia.org/w/index.php?curid=132773308

British PrecisionLife Ltd and the Metrodora Institute have announced to launch clinical trials to improve the diagnosis and therapy of long COVID-related ME/CFS.

© AC Immune

AC Immune and Takeda have inked an exclusive option license agreement for ACI-24.060, a first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression.

Fundus of patient with teinitis pigmentosa. © By Christian Hamel - wikimedia.org

AI specialist WhiteLab Genomics, the Vision Institute, and IT expert ADLIN Science, have entered into a strategic partnership aimed at developing new AAV vectors targetting retinal dystrophies.

Corporate headquarters of Jazz Pharmaceuticals are located in Dublin, Ireland. © Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc has entered an agreement with Redx Pharma to acquire commercialisation rights to Redx KRAS blockers, which include G12D selective and pan-KRAS molecules.